SUBSCRIBE
SUBSCRIBE
News   Drug Development

ProMetic Life Sciences Inc. Reports Positive Preliminary Phase Ib/II Data for PBI-1402 in Chemotherapy-Induced Anemia

July 10, 2007 | 
1 min read

MONTREAL, QUEBEC--(MARKET WIRE)--Jul 10, 2007 -- ProMetic Life Sciences Inc. (Toronto:PLI.TO - News) (“ProMetic”) announces preliminary data from a Phase Ib/II trial with its orally active drug PBI-1402 for the treatment of chemotherapy-induced anemia (CIA). Data highlights include:

Clinical research Phase I Phase II
MORE ON THIS TOPIC
Speech balloon conversation in puzzle shape vector illustration card. Human hands exchange information in retro 80s collage vector illustration. Concept of success in communication, support, cooperation; new projects, professional growth.
Immunology and inflammation
Pliant Brings in Outside Experts to Review IPF Study Pause
February 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Vaccines
Sanofi Hit With $250M Impairment After Scrapping J&J-Partnered E. coli Vaccine
February 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Female alcoholism concept. Unhappy woman sitting at bottle bottom hugging her knees. Sad drunk wife or alcoholic mother. Social issue, abuse, addiction. Empty alcohol drink bottles vector Illustration
GLP-1
Novo’s Semaglutide Shows Promise for Alcohol Use Disorder
February 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and falling coins in orange circle. Modern design of finance and business.
Neuropsychiatric disorders
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
February 13, 2025
 · 
3 min read
 · 
Dan Samorodnitsky